Cizzle Biotechnology to take early lung cancer test to £3b China market (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss a full commercial development and royalty agreement to develop and market Cizzle Biotechnologies early lung cancer diagnostic tests in China.

Allan provides us with more information around the deal, tells us about the diagnostic technology and what it does, explains who its partners are in China and how this arrangement in China will work from a financial point of view and potentially generate future revenues for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading  Cizzle Biotechnology update on development of proprietary antibodies

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Cizzle Biotechnology to take early lung cancer test to £3b China market (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions